BioSpace News Archive

GT Biopharma, Inc. announced today it had completed treatment of patients enrolled at Dose Levels 1 and 2, and begun enrolling patients for treatment at Dose Level 3, in its GTB-3550

Pear Therapeutics to Participate in the 2020 BTIG Virtual Biotechnology Conference and the Canaccord Genuity 40 th Annual Growth Conference

- Mino-Wrap being developed for the reduction of post-operative infections associated with breast reconstruction surgery - Mino-Wrap is the second major drug development collaboration with MD Anderson Cancer Center

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in August: BTIG Virtual Biotechnology Conference 2020 Tuesday, August 11, 2020 at 11:00 a.m. Eastern Time Canaccord Genuity 40th Annual Growth Conference Wednesday, August 12, 2020 at 1:00 p.m. Eastern Time A live audio webcast of the presentations can be acces

REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, reported positive one year data from patients in Cohorts 4 and 5 of the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration.

T-Cure Bioscience, Inc. announced that the Company has extended its ongoing research collaboration with the National Heart Lung and Blood Institute, through a formal Collaborative Research and Development Agreement to advance the Company’s HERV-E targeting TCR therapy for renal cell cancer.

Second Quarter 2020 XPOVIO Net Product Sales of $18.6 Million; Strongest Quarterly Sales Since July 2019 Launch

Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2020 financial results.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, reported financial results for the second quarter ended June 30, 2020.

Simulations Plus, Inc., a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.